BioNTech

BioNTech SE is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer. The company has developed an mRNA-based human therapeutic for intravenous administration to bring individualized mRNA-based cancer immunotherapy to clinical trials and to establish its own manufacturing process.

Read more in the app

Biontech is planning cancer vaccines before 2030

Pfizer Covid-19 Bivalent Vaccine And Stroke Risk: What You Need To Know

BioNTech begins experimental genital herpes mRNA vaccine trial

BioNTech Founders Predict Cancer Vaccine Is Only Years Away

Moderna Sues Pfizer and BioNTech Over Covid Vaccine Technology

Pfizer And BioNTech Ask FDA To Authorize Omicron Covid Booster

mRNA Cancer Treatment: Covid Vaccine Giant BioNTech Touts Promising Early Data

Covid-19 news: Pfizer/BioNTech vaccine treats covid for first time

Covid-19 news: Pfizer/BioNTech jab may be less effective in under 12s

New Study Shows 3 Doses of Pfizer–BioNTech COVID Vaccine Better Than 2

New Study Shows Third Dose of Pfizer-BioNTech COVID Vaccine May Protect Against Omicron

The FDA And CDC Greenlight Booster Shots Of Pfizer-BioNTech’s Covid Vaccine For 16- And 17-Year-Olds

Pfizer & BioNTech will soon seek approval for COVID-19 vaccine in young children

Pfizer and BioNTech Press Ahead on Booster Shots

F.D.A. Fully Approves Pfizer Vaccine

FDA grants full approval for Pfizer-BioNTech coronavirus vaccine

BioNTech Stock Jumps Thanks To Imminent FDA Vaccine Approval

Pfizer&BioNTech develop the third shot against delta variant

Pfizer-BioNTech vaccine in patients undergoing cancer treatment

Moderna and Pfizer-BioNTech vaccines prime T cells to fight SARS-CoV-2 variants, study finds